1. Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Advances in Experimental Medicine and Biology 2014; 810:120-40. [
DOI:10.1007/978-1-4939-0437-2_7]
2. Gladfelter P, Darwish NH and Mousa SA. Current status and future direction in the management of malignant melanoma. Melanoma Res. 2017; 27 (5): 403-10. [
DOI:10.1097/CMR.0000000000000379]
3. Ma C and Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. Journal of Dermatological Treatment 2014; 25 (5): 401-8. [
DOI:10.3109/09546634.2013.813897]
4. Menaa F. Latest approved therapies for metastatic melanoma: what comes next? Journal of Skin Cancer. 2013; 2013. [
DOI:10.1155/2013/735282]
5. Menzies AM and Long GV. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. European J. Cancer (Oxford, England: 1990). 2013; 49 (15): 3229-41. [
DOI:10.1016/j.ejca.2013.06.027]
6. Mao JJ, Palmer CS, Healy KE, Desai K and Amsterdam J. Complementary and alternative medicine use among cancer survivors: a population-based study. J. Cancer Survivorship 2011; 5 (1): 8-17. [
DOI:10.1007/s11764-010-0153-7]
7. Sato A. Rationales for traditional medicines utilisation and its equity implications: the case of Ghana: The London School of Economics and Political Science (LSE); 2012.
8. Adams J, Andrews G, Barnes J, Broom A and Magin P. Traditional, complementary and integrative medicine: an international reader: Palgrave Macmillan; 2012. [
DOI:10.1007/978-1-137-26559-3]
9. Qi Z and Kelley E. The WHO traditional medicine strategy 2014-2023: a perspective. Science 2014; 346 (6216): S5-S6.
10. Laleh H and, Vaferi R. History of evolution of traditional medicine to modern medicine in Gajar age. Journal Humanities Research University 2006; 16 (60): 131‐164. [In Persian].
11. Hysen P. Timeline of Graeco-Arabic Medicine. In: An introduction to Graeco-Arabic Medicine: Graeco-Arabic Medicine Society Inc; 2000 [cited 2014 7 Oct]. Available from: http://www.traditionalmedicine.net.au/graecarb.htm.
12. Elgood C. A medical history of Persia and the eastern caliphate: From the earliest times until the year AD 1932, Cambridge University Press; 2010. [
DOI:10.1017/CBO9780511710766]
13. Zargaran A. Ancient Persian medical views on the heart and blood in the Sassanid era (224-637 AD). International J. Cardiology 2014; 172 (2): 307-12. [
DOI:10.1016/j.ijcard.2014.01.035]
14. Bennison AK. The great caliphs: the golden age of the'Abbasid Empire: Yale University Press; 2014.
15. Browne EG. Islamic Medicine, 2002. ISBN 81-87570-19-9; 1921.
16. Dalfardi B, Daneshfard B and Nezhad GSM. Johannitius (809-873 AD), a medieval physician, translator and author. J. Medical Biography 2016; 24 (3): 328-30. [
DOI:10.1177/0967772014532890]
17. Kelishadi R and Hatami H. Avicenna as the forerunner of preventive medicine: On the occasion of 1032nd birth anniversary of Avicenna (22 August 980). International J. Preventive Medicine 2012; 3 (8): 517.
18. Margaret M, Olszewski. Concepts of Cancer from Antiquity to the Nineteenth Century. UTMJ. 2010; 87: 181-6. [
DOI:10.5015/utmj.v87i3.1252]
19. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA and Eheman CR. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014; 120: 1290-1314. [
DOI:10.1002/cncr.28509]
20. Zhang G, Yang P, Guo P, Miele L, Sarkar FH, Wang Z and Zhou Q. Unraveling the mystery of cancer metabolism in the genesis of tumor-initiating cells and development of cancer. Biochim. Biophys. Acta. 2013; 1836: 49-59. [
DOI:10.1016/j.bbcan.2013.03.001]
21. Emami SA, Sahebkar A, Tayarani-Najaran N and Tayarani-Najaran Z. Cancer and its treatment in main ancient books of Islamic Iranian traditional medicine (7th to 14th century AD). Iranian Red. Crescent. Medical J. 2012; 14 (12): 747. [
DOI:10.5812/ircmj.4954]
22. Azam Khan M. Exir Azam, Vol.1. Tehran: Institute of Meical History, Islamic Medicine and Complementary Medicine; 2008. (in Persian)
23. Jorjani E. Zakhireye Kharazm Shahi (Treasure of Kharazm Shah), In: Moharreri MR, editor. Vol.2. Tehran: Iranian Medical Academy; 2001 (in Persian).
24. Naghibi F, Khalaj A and Moghadam MH. Cancer terminologies used in the medieval texts to the early modern Iranian traditional medicine (ITM). Journal of Research on History of Medicine 2014; 3 (2 May):63-70.
25. Razes. Al Havi [Liber Continent]. Beiruot: Ehyaol Toras al-Arabi Press; 2001. (in Arabic)
26. Kermani, Nafis-ebn-e-avaz, Sharholasbab-va-Alalamat, Qom, Jalaledin press, 1367, pp: 425-450. (In Arabic)
27. A. Ganon. Tehran, Iran: darotebao alijah aligholikhan; 1297, p: several pages. (in Arabic)
28. Shirbeigi L, Iranzadasl M, Mansouri P, Hejazi S and Aliasl J. Skin Aging Remedies in Traditional Persian Medicine. Journal of Skin and Stem Cell 2015; 2 (1): e30283. [
DOI:10.17795/jssc3028]
29. Arzani MA. In: Teb-e-Akbari [Akbari's Medicine]. Ehya Teb e Tabiee O, editor. Tehran: Jalaleddin Press; 2008, pp. 641-2. (in Persian).
30. Moeini R, Gorji N, Rezaeizadeh H, Pasalar P, Nazem E and Kamalinejad M. Etiology and treatment of cancer; view point of Persian medicine. Medical History J. 2017; 9 (30): 55-82.
31. Tabatabaei SM and Tabatabaei SMA. Diagnosis and treatment of cancer in medical textbooks of ancient Iran. J. Medical Ethics and History of Medicine 2014; 7: 16.
32. Gorji N, Moeini R, Pasalar P, Rezaeizadeh H, Kamalinejad M and Nazem E. Cancer Biopsy in Ancient Persian Medicine: Do or Not to Do! Iranian J. Public Health 2015; 44 (10): 1440-1.
33. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2017. CA: A Cancer J. for Clinicians 2017; 67 (1): 7-30. [
DOI:10.3322/caac.21387]
34. Razi S, Rafiemanesh H, Ghoncheh M, Khani Y and Salehiniya H. Changing trends of types of skin cancer in Iran. Asian Pac. J. Cancer Prev. 2015; 16 (12): 4955-8. [
DOI:10.7314/APJCP.2015.16.12.4955]
35. Kim RH and Armstrong AW. Nonmelanoma Skin Cancer Dermatol Clin. 2011; 30: 125-139. [
DOI:10.1016/j.det.2011.08.008]
36. Koosha A, Farahbakhsh M, Hakimi S, Abdolahi L, Golzari M and Seyf Farshad M. Epidemiologic assessment of cancer disease in east Azerbaijan 2007. Med. J. Tabriz Univ. Med. Sci. 2010; 32: 74-79. (in Persian).
37. Woźniak A, Szyfter K, Szyfter W and Florek E. Head and neck cancer--history. Przeglad Lekarski. 2012; 69 (10): 1079-83.
38. Lai V, Cranwell W and Sinclair R. Epidemiology of skin cancer in the mature patient. Clin. Dermatol. 2018; 36(2): 167-76. [
DOI:10.1016/j.clindermatol.2017.10.008]
39. Atarzadeh F, Heydari M, Sanaye MR and Amin G. Avicenna-A Pioneer in Dermatology. JAMA Dermatol. 2016; 152(11): 1257. [
DOI:10.1001/jamadermatol.2016.0026]
40. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P and et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. European J. Cancer. 2005; 41 (1): 28-44. [
DOI:10.1016/j.ejca.2004.10.015]
41. Constant E. Risk factors for cutaneous melanoma: A practical method of recognizing predisposed individuals. Plastic and Reconstructive Surgery 1989; 83 (4): 761. [
DOI:10.1097/00006534-198904000-00085]
42. Katta R and Brown DN. Diet and skin cancer: The potential role of dietary antioxidants in nonmelanoma skin cancer prevention. J. Skin Cancer. 2015; 1:10. Article ID 893149 [
DOI:10.1155/2015/893149]
43. Park MK, Li WQ, Qureshi AA and Cho E. Fat Intake and Risk of Skin Cancer in U.S. Adults. J. Cancer Epidemiology, Biomarkers & Prevention 2018; 27 (7): 776-82. [
DOI:10.1158/1055-9965.EPI-17-0782]
44. Russak JE and Rigel DS. Risk factors for the development of primary cutaneous melanoma. Dermatologic Clinics 2012; 30 (3): 363-8. [
DOI:10.1016/j.det.2012.05.002]
45. Curiel-Lewandrowski C, Chen SC and Swetter SM. Screening and Prevention Measures for Melanoma: Is There a Survival Advantage? Current Oncology Reports 2012; 14: 458-467. [
DOI:10.1007/s11912-012-0256-6]